Novo Nordisk announced the launch of a new subscription program that will offer discounted multi-month supplies of its Wegovy obesity medication to self-paying patients in the United States. The program targets patients who do not have insurance coverage for the weight-loss drug.

Wegovy, which contains the active ingredient semaglutide, has become one of the most sought-after obesity treatments since receiving FDA approval. The medication has demonstrated significant weight loss results in clinical trials, leading to high demand that has periodically outstripped supply.

The subscription model represents Novo Nordisk's effort to maintain competitiveness in the rapidly growing obesity drug market. The Danish pharmaceutical company faces increasing competition from rivals including Eli Lilly, which has been gaining market share with its own weight-loss medications.

The new pricing structure aims to make Wegovy more accessible to patients who pay out-of-pocket, as the medication's list price has been a barrier for many seeking treatment. Insurance coverage for obesity medications remains inconsistent across different health plans, leaving many patients to cover the full cost themselves.

The announcement comes as the obesity drug market continues to expand rapidly, with pharmaceutical companies racing to capture market share in what analysts project will become a multi-billion dollar therapeutic area. Both Novo Nordisk and its competitors have been working to scale up manufacturing capacity to meet growing demand for these medications.